Feng R, Cheng DX, Song T, Chen L, Lu KP. Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy. World J Gastrointest Surg 2023; 15(4): 687-697 [PMID: 37206075 DOI: 10.4240/wjgs.v15.i4.687]
Corresponding Author of This Article
Kai-Ping Lu, MM, Associate Chief Physician, Department of Vascular Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Gongshu District, Hangzhou 310000, Zhejiang Province, China. lukaiping158@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Apr 27, 2023; 15(4): 687-697 Published online Apr 27, 2023. doi: 10.4240/wjgs.v15.i4.687
Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy
Rui Feng, De-Xin Cheng, Tao Song, Long Chen, Kai-Ping Lu
Rui Feng, De-Xin Cheng, Department of Interventional Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang Province, China
Tao Song, Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang Province, China
Long Chen, Department of Radiotherapy, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang Province, China
Kai-Ping Lu, Department of Vascular Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang Province, China
Author contributions: Feng R and Lu KP designed the study and wrote the manuscript; Feng R and Cheng DX analyzed the data; Song T and Chen L were responsible for revising the paper; all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study was approved by Ethics Committee of the Third Hospital of Zhejiang Provincial People’s Hospital.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kai-Ping Lu, MM, Associate Chief Physician, Department of Vascular Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Gongshu District, Hangzhou 310000, Zhejiang Province, China. lukaiping158@126.com
Received: January 17, 2023 Peer-review started: January 17, 2023 First decision: March 1, 2023 Revised: March 9, 2023 Accepted: March 23, 2023 Article in press: March 23, 2023 Published online: April 27, 2023 Processing time: 95 Days and 20.1 Hours
ARTICLE HIGHLIGHTS
Research background
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. Transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) is the recommended treatment for intermediate HCC according to the Barcelona Clinic Liver Cancer guidelines.
Research motivation
TARE, as a new interventional therapy, has been gradually applied to the treatment of advanced HCC, and has a good effect on the treatment of advanced HCC.
Research objectives
To explore the efficacy and safety of TACE+TARE in the advanced HCC descending hepatectomy.
Research methods
The patients in the control group and the observation group were compared in terms of focal inactivation, tumor nodule size, lipiodol deposition, serum alpha-fetoprotein (AFP) level in different periods, postoperative complications, 1-year survival rate, and adverse reactions.
Research results
Compared with the control group, the observation group can be effective, reduce tumor nodules, reducing postoperative AFP value, reducing postoperative complications, and relieving clinical symptoms. Compared with the control group, the observation group significantly increased the deposition of lipiodol, expanded the scope of tumor necrosis, increased the 1-year survival rate of patients after surgery, and reduced adverse reactions, the difference was statistically significant (P < 0.05).
Research conclusions
Compared with TACE, TACE + TARE is more effective in the treatment of patients with advanced HCC.
Research perspectives
This study may provide a clinical basis for the treatment of patients with advanced HCC.
